Restoring Balance In The Gut To Prevent Drug-Resistant Infection
Silvia Caballero, one of In Vivo’s 2020 Rising Leaders, is heading up Vedanta’s efforts to prevent potentially lethal infections stemming from colonization of the gut microbiome with a novel bacterial cocktail that is nearing clinical development.
You may also be interested in...
Vedanta’s latest financing allows it to push three of its microbiome-based drug candidates further into the clinic, with big name partners such as BMS and Janssen onboard.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.